Last reviewed · How we verify

Metoprolole (Selo-Zok ®)

Rigshospitalet, Denmark · FDA-approved active Small molecule

Metoprolole (Selo-Zok ®) is a Beta-1 selective adrenergic antagonist (beta-blocker) Small molecule drug developed by Rigshospitalet, Denmark. It is currently FDA-approved for Hypertension, Angina pectoris, Acute myocardial infarction.

Metoprolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate and blood pressure by blocking the effects of norepinephrine and epinephrine on the heart.

Metoprolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate, blood pressure, and cardiac workload. Used for Hypertension, Angina pectoris, Myocardial infarction (secondary prevention).

At a glance

Generic nameMetoprolole (Selo-Zok ®)
SponsorRigshospitalet, Denmark
Drug classBeta-1 selective adrenergic antagonist (beta-blocker)
TargetBeta-1 adrenergic receptor
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Metoprolol competitively blocks beta-1 adrenergic receptors on cardiac tissue, decreasing heart contractility and heart rate. This reduces cardiac oxygen demand and blood pressure, making it effective for hypertension and angina. It also has antiarrhythmic properties useful in atrial fibrillation management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Metoprolole (Selo-Zok ®)

What is Metoprolole (Selo-Zok ®)?

Metoprolole (Selo-Zok ®) is a Beta-1 selective adrenergic antagonist (beta-blocker) drug developed by Rigshospitalet, Denmark, indicated for Hypertension, Angina pectoris, Acute myocardial infarction.

How does Metoprolole (Selo-Zok ®) work?

Metoprolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate and blood pressure by blocking the effects of norepinephrine and epinephrine on the heart.

What is Metoprolole (Selo-Zok ®) used for?

Metoprolole (Selo-Zok ®) is indicated for Hypertension, Angina pectoris, Acute myocardial infarction, Heart failure, Atrial fibrillation.

Who makes Metoprolole (Selo-Zok ®)?

Metoprolole (Selo-Zok ®) is developed and marketed by Rigshospitalet, Denmark (see full Rigshospitalet, Denmark pipeline at /company/rigshospitalet-denmark).

What drug class is Metoprolole (Selo-Zok ®) in?

Metoprolole (Selo-Zok ®) belongs to the Beta-1 selective adrenergic antagonist (beta-blocker) class. See all Beta-1 selective adrenergic antagonist (beta-blocker) drugs at /class/beta-1-selective-adrenergic-antagonist-beta-blocker.

What development phase is Metoprolole (Selo-Zok ®) in?

Metoprolole (Selo-Zok ®) is FDA-approved (marketed).

What are the side effects of Metoprolole (Selo-Zok ®)?

Common side effects of Metoprolole (Selo-Zok ®) include Fatigue, Dizziness, Bradycardia, Hypotension, Dyspnea, Depression.

What does Metoprolole (Selo-Zok ®) target?

Metoprolole (Selo-Zok ®) targets Beta-1 adrenergic receptor and is a Beta-1 selective adrenergic antagonist (beta-blocker).

Related